ATE515577T1 - Verwendung von mit der wirksamkeit der behandlung einer entzündungskrankheit assoziierten genetischen polymorphismen - Google Patents
Verwendung von mit der wirksamkeit der behandlung einer entzündungskrankheit assoziierten genetischen polymorphismenInfo
- Publication number
- ATE515577T1 ATE515577T1 AT04765831T AT04765831T ATE515577T1 AT E515577 T1 ATE515577 T1 AT E515577T1 AT 04765831 T AT04765831 T AT 04765831T AT 04765831 T AT04765831 T AT 04765831T AT E515577 T1 ATE515577 T1 AT E515577T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- inflammatory disease
- genetic polymorphisms
- effectiveness
- polymorphisms associated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Transplantation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50897103P | 2003-10-06 | 2003-10-06 | |
PCT/EP2004/011124 WO2005040416A1 (en) | 2003-10-06 | 2004-10-05 | Use of genetic polymorphisms that associate with efficacy of treatment of inflammatory disease |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE515577T1 true ATE515577T1 (de) | 2011-07-15 |
Family
ID=34520002
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04765831T ATE515577T1 (de) | 2003-10-06 | 2004-10-05 | Verwendung von mit der wirksamkeit der behandlung einer entzündungskrankheit assoziierten genetischen polymorphismen |
Country Status (13)
Country | Link |
---|---|
US (1) | US20070155772A1 (de) |
EP (1) | EP1673473B1 (de) |
JP (1) | JP2007507460A (de) |
CN (1) | CN1890384A (de) |
AT (1) | ATE515577T1 (de) |
AU (1) | AU2004283235B2 (de) |
BR (1) | BRPI0415302A (de) |
CA (1) | CA2541138A1 (de) |
ES (1) | ES2367566T3 (de) |
MX (1) | MXPA06003828A (de) |
PL (1) | PL1673473T3 (de) |
PT (1) | PT1673473E (de) |
WO (1) | WO2005040416A1 (de) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2272544A1 (de) | 2003-03-28 | 2011-01-12 | Conor Medsystems, Inc. | Implantierbare medizinische Vorrichtung enthaltend eine therapeutische Substanz in einem Konzentrationsgradient. |
EP3578205A1 (de) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | Pharmazeutische zusammensetzungen enthaltenbearbeitete nukleinsäuren und ihre medizinische verwendung |
WO2012045082A2 (en) | 2010-10-01 | 2012-04-05 | Jason Schrum | Engineered nucleic acids and methods of use thereof |
US20120283112A1 (en) | 2011-02-22 | 2012-11-08 | The Procter & Gamble Company | Systems and Methods for Identifying Cosmetic Agents for Skin Care Compositions |
AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
MX2013010977A (es) | 2011-03-31 | 2013-10-30 | Procter & Gamble | Sistema, modelos y metodos para identificar y evaluar agentes dermoactivos eficaces para tratar la caspa/dermatitis seborreica. |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
EP3682905B1 (de) | 2011-10-03 | 2021-12-01 | ModernaTX, Inc. | Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon |
DK2791160T3 (da) | 2011-12-16 | 2022-05-30 | Modernatx Inc | Modificerede mrna-sammensætninger |
JP2015512261A (ja) | 2012-03-30 | 2015-04-27 | ザ プロクター アンド ギャンブルカンパニー | 色素沈着過剰状態の遺伝子発現シグネチャーを生成する方法 |
DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
JP2015527630A (ja) | 2012-06-06 | 2015-09-17 | ザ プロクター アンド ギャンブルカンパニー | ヘア/頭皮ケア組成物向け化粧剤の同定システム及び方法 |
EP2885426B1 (de) | 2012-08-15 | 2020-10-07 | The Procter and Gamble Company | Systeme, modelle und verfahren zur identifizierung und beurteilung von hautpflegemitteln zur behandlung einer reihe von hauterkrankungen |
HRP20220607T1 (hr) | 2012-11-26 | 2022-06-24 | Modernatx, Inc. | Terminalno modificirana rna |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
EP3052521A1 (de) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynukleotide zur codierung von low-density-lipoprotein-rezeptor |
ES2548793B1 (es) * | 2014-03-17 | 2016-07-07 | Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Princesa | Método pronóstico de enfermedades autoinmunes mediante el genotipado de variantes genéticas del péptido intestinal vasoactivo |
US10295527B2 (en) | 2016-03-14 | 2019-05-21 | Bruce Yacyshyn | Process and system for predicting responders and non-responders to mesalamine treatment of ulcerative colitis |
US11946927B2 (en) | 2016-03-14 | 2024-04-02 | Musidora Biotechnology Llc | Process and system for identifying individuals having a high risk of inflammatory bowel disease and a method of treatment |
KR20240095363A (ko) * | 2016-05-20 | 2024-06-25 | 세다르스-신나이 메디칼 센터 | 유전자에 기반한 염증성 장 질환의 진단 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0288088B1 (de) * | 1987-04-24 | 1994-03-09 | Teijin Limited | Bestimmung vom Tumornekrosefaktor; monoklonaler Antikörper und Zusammensetzung |
US6235723B1 (en) * | 1992-03-16 | 2001-05-22 | Isis Pharmaceuticals , Inc. | Antisense oligonucleotide modulation of human protein kinase C-δ expression |
BR0209474A (pt) * | 2001-05-09 | 2006-02-07 | Novartis Ag | Métodos para imunomodulação seletiva |
-
2004
- 2004-10-05 PL PL04765831T patent/PL1673473T3/pl unknown
- 2004-10-05 PT PT04765831T patent/PT1673473E/pt unknown
- 2004-10-05 WO PCT/EP2004/011124 patent/WO2005040416A1/en active IP Right Grant
- 2004-10-05 JP JP2006530098A patent/JP2007507460A/ja active Pending
- 2004-10-05 ES ES04765831T patent/ES2367566T3/es active Active
- 2004-10-05 CA CA002541138A patent/CA2541138A1/en not_active Abandoned
- 2004-10-05 AU AU2004283235A patent/AU2004283235B2/en not_active Ceased
- 2004-10-05 CN CNA2004800358001A patent/CN1890384A/zh active Pending
- 2004-10-05 AT AT04765831T patent/ATE515577T1/de active
- 2004-10-05 EP EP04765831A patent/EP1673473B1/de active Active
- 2004-10-05 US US10/574,770 patent/US20070155772A1/en not_active Abandoned
- 2004-10-05 MX MXPA06003828A patent/MXPA06003828A/es not_active Application Discontinuation
- 2004-10-05 BR BRPI0415302-2A patent/BRPI0415302A/pt not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CN1890384A (zh) | 2007-01-03 |
WO2005040416A1 (en) | 2005-05-06 |
PT1673473E (pt) | 2011-09-19 |
US20070155772A1 (en) | 2007-07-05 |
CA2541138A1 (en) | 2005-05-06 |
EP1673473B1 (de) | 2011-07-06 |
ES2367566T3 (es) | 2011-11-04 |
AU2004283235B2 (en) | 2007-08-02 |
PL1673473T3 (pl) | 2011-12-30 |
EP1673473A1 (de) | 2006-06-28 |
JP2007507460A (ja) | 2007-03-29 |
MXPA06003828A (es) | 2006-06-14 |
AU2004283235A1 (en) | 2005-05-06 |
BRPI0415302A (pt) | 2006-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE515577T1 (de) | Verwendung von mit der wirksamkeit der behandlung einer entzündungskrankheit assoziierten genetischen polymorphismen | |
Langston et al. | Retinoic acid-responsive enhancers located 3 of the Hox A and Hox B homeobox gene clusters: functional analysis | |
ATE437962T1 (de) | Verfahren für die behandlung von proliferativen erkrankungen von brustzellen | |
EP2631293A3 (de) | Menschliche Mikro-RNAs und Verfahren zur Hemmung davon | |
DE60330841D1 (de) | Überexpression von extremozymgenen in pseudomonas und nahe verwandte bakterien | |
ATE526407T1 (de) | Insektenresistenz durch inhibierung von genexpression | |
EP1490489A4 (de) | Verfahren und mittel zur überwachung und modulation des gen-silencing | |
WO2005087953A8 (en) | Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof | |
DK1730315T3 (da) | Polymorphismer i NOD2/Card15 gen | |
WO2005059172A3 (en) | Method and nucleic acids for the improved treatment of breast cell proliferative disorders | |
WO2007085497A3 (en) | Markers for the prediction of outcome of anthracycline treatment | |
ATE513929T1 (de) | Gene mit einfluss auf die menschliche gedächtnisleistung | |
ATE309812T1 (de) | Verwendung von adenoviren mit mutationen in den va-genen für die krebstherapie | |
WO2008051511A3 (en) | Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof | |
WO2005112568A3 (en) | Haplotype markers and methods of using the same to determine response to treatment | |
WO2004015087A3 (en) | Eukaryotic genes involved in adult lifespan regulation | |
Chauhan et al. | Genome-wide association analysis identified splicing single nucleotide polymorphism in CFLAR predictive of triptolide chemo-sensitivity | |
ES2536002T3 (es) | Marcadores para células pre-cancerígenas y cancerígenas y el método para interferir con la proliferación celular en ellas | |
MX2009008788A (es) | Poliformismos de serpine1 son predictivos de respuesta a administracion de proteina c activada y riesgo de muerte. | |
Kim et al. | Efficient sequence-directed psoralen targeting using pseudocomplementary peptide nucleic acids | |
MX2013013023A (es) | Analisis y metodo para la identificacion de la capacidad de respuestas individual a tratamiento con inmunoglobulina. | |
AU2003276872A1 (en) | Methods for identifying antimicrobial compounds | |
ATE465248T1 (de) | Humane cyclooxygenase-3 und ihre verwendung | |
ATE555201T1 (de) | Verwendung von sirna zur abschaffung der expression von eif-5a1 in der behandlung von glaukoma | |
DE50015171D1 (de) | Rna polymerase i transkriptionsfaktor tif-ia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1673473 Country of ref document: EP |